logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

ES-SCLC: better outcomes with combination therapy than with chemotherapy alone

Biggest survival boost came with adding bevacizumab or PD-L1 inhibitors.